Drug Information

Baycol Information

FDA announced on August 8, 2001 that Bayer Pharmaceutical Division is voluntarily withdrawing Baycol (cerivastatin) from the U.S. market because of reports of sometimes fatal rhabdomyolysis, a severe muscle adverse reaction from this cholesterol-lowering (lipid-lowering) product. The FDA agrees with and supports this decision.

• Baycol Talk Paper (8/8/2001)
• Baycol Questions and Answers (8/8/2001)
• Dear Healthcare Professional Letter (8/8/2001)

Back to Top   Drug Information

FDA/Center for Drug Evaluation and Research
Last Updated: August 08, 2001
Originator: OTCOM/DLIS
HTML by MAU